 | • レポートコード：MRC2-11QY13561 • 出版社/出版日：QYResearch / 2020年11月30日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は急性冠症候群（ACS）のグローバル市場について調査・分析したレポートです。種類別（単剤療法、併用療法）市場規模、用途別（病院、外来手術センター、診断センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別急性冠症候群（ACS）の競争状況、市場シェア ・世界の急性冠症候群（ACS）市場：種類別市場規模 2015年-2020年（単剤療法、併用療法） ・世界の急性冠症候群（ACS）市場：種類別市場規模予測 2021年-2026年（単剤療法、併用療法） ・世界の急性冠症候群（ACS）市場：用途別市場規模 2015年-2020年（病院、外来手術センター、診断センター） ・世界の急性冠症候群（ACS）市場：用途別市場規模予測 2021年-2026年（病院、外来手術センター、診断センター） ・北米の急性冠症候群（ACS）市場分析：米国、カナダ ・ヨーロッパの急性冠症候群（ACS）市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの急性冠症候群（ACS）市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の急性冠症候群（ACS）市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの急性冠症候群（ACS）市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Dexa Medica、GlaxoSmithKline、Novartis、Pfizer、Sanofi、Serum Institute of India、Biogen Inc、Eli Lilly and Company ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Acute coronary syndrome (ACS) is a syndrome (set of signs and symptoms) due to decreased blood flow in the coronary arteries such that part of the heart muscle is unable to function properly or dies. The most common symptom is chest pain, often radiating to the left shoulder or angle of the jaw, crushing, central and associated with nausea and sweating. Many people with acute coronary syndromes present with symptoms other than chest pain, particularly, women, older patients, and patients with diabetes mellitus.
Increase in geriatric population and rise in the incidence of cardiac disorders are the major factors that drive the market growth. However, stringent government regulations for the approval of drugs are expected to restrain the market growth. Improvement in healthcare facilities in emerging regions such as Asia-Pacific and LAMEA are expected to provide new growth opportunities for the market during the analysis period.
Market Analysis and Insights: Global Acute Coronary Syndrome (ACS) Market
The global Acute Coronary Syndrome (ACS) market size is projected to reach US$ 8120.8 million by 2026, from US$ 7806.3 million in 2020, at a CAGR of 3.7%% during 2021-2026.
Global Acute Coronary Syndrome (ACS) Scope and Market Size
Acute Coronary Syndrome (ACS) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Acute Coronary Syndrome (ACS) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Dexa Medica
GlaxoSmithKline
Novartis
Pfizer
Sanofi
Serum Institute of India
Biogen Inc
Eli Lilly and Company
Market segment by Type, the product can be split into
Monotherapy
Combination Therapy
Market segment by Application, split into
Hospitals
Ambulatory Surgical Center
Diagnostic Centers
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Acute Coronary Syndrome (ACS) Revenue
1.4 Market by Type
1.4.1 Global Acute Coronary Syndrome (ACS) Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Monotherapy
1.4.3 Combination Therapy
1.5 Market by Application
1.5.1 Global Acute Coronary Syndrome (ACS) Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Ambulatory Surgical Center
1.5.4 Diagnostic Centers
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Acute Coronary Syndrome (ACS) Market Perspective (2015-2026)
2.2 Global Acute Coronary Syndrome (ACS) Growth Trends by Regions
2.2.1 Acute Coronary Syndrome (ACS) Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Acute Coronary Syndrome (ACS) Historic Market Share by Regions (2015-2020)
2.2.3 Acute Coronary Syndrome (ACS) Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Acute Coronary Syndrome (ACS) Market Growth Strategy
2.3.6 Primary Interviews with Key Acute Coronary Syndrome (ACS) Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Acute Coronary Syndrome (ACS) Players by Market Size
3.1.1 Global Top Acute Coronary Syndrome (ACS) Players by Revenue (2015-2020)
3.1.2 Global Acute Coronary Syndrome (ACS) Revenue Market Share by Players (2015-2020)
3.1.3 Global Acute Coronary Syndrome (ACS) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Acute Coronary Syndrome (ACS) Market Concentration Ratio
3.2.1 Global Acute Coronary Syndrome (ACS) Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Acute Coronary Syndrome (ACS) Revenue in 2019
3.3 Acute Coronary Syndrome (ACS) Key Players Head office and Area Served
3.4 Key Players Acute Coronary Syndrome (ACS) Product Solution and Service
3.5 Date of Enter into Acute Coronary Syndrome (ACS) Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Acute Coronary Syndrome (ACS) Historic Market Size by Type (2015-2020)
4.2 Global Acute Coronary Syndrome (ACS) Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Acute Coronary Syndrome (ACS) Market Size by Application (2015-2020)
5.2 Global Acute Coronary Syndrome (ACS) Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Acute Coronary Syndrome (ACS) Market Size (2015-2020)
6.2 Acute Coronary Syndrome (ACS) Key Players in North America (2019-2020)
6.3 North America Acute Coronary Syndrome (ACS) Market Size by Type (2015-2020)
6.4 North America Acute Coronary Syndrome (ACS) Market Size by Application (2015-2020)
7 Europe
7.1 Europe Acute Coronary Syndrome (ACS) Market Size (2015-2020)
7.2 Acute Coronary Syndrome (ACS) Key Players in Europe (2019-2020)
7.3 Europe Acute Coronary Syndrome (ACS) Market Size by Type (2015-2020)
7.4 Europe Acute Coronary Syndrome (ACS) Market Size by Application (2015-2020)
8 China
8.1 China Acute Coronary Syndrome (ACS) Market Size (2015-2020)
8.2 Acute Coronary Syndrome (ACS) Key Players in China (2019-2020)
8.3 China Acute Coronary Syndrome (ACS) Market Size by Type (2015-2020)
8.4 China Acute Coronary Syndrome (ACS) Market Size by Application (2015-2020)
9 Japan
9.1 Japan Acute Coronary Syndrome (ACS) Market Size (2015-2020)
9.2 Acute Coronary Syndrome (ACS) Key Players in Japan (2019-2020)
9.3 Japan Acute Coronary Syndrome (ACS) Market Size by Type (2015-2020)
9.4 Japan Acute Coronary Syndrome (ACS) Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Acute Coronary Syndrome (ACS) Market Size (2015-2020)
10.2 Acute Coronary Syndrome (ACS) Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Acute Coronary Syndrome (ACS) Market Size by Type (2015-2020)
10.4 Southeast Asia Acute Coronary Syndrome (ACS) Market Size by Application (2015-2020)
11 India
11.1 India Acute Coronary Syndrome (ACS) Market Size (2015-2020)
11.2 Acute Coronary Syndrome (ACS) Key Players in India (2019-2020)
11.3 India Acute Coronary Syndrome (ACS) Market Size by Type (2015-2020)
11.4 India Acute Coronary Syndrome (ACS) Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Acute Coronary Syndrome (ACS) Market Size (2015-2020)
12.2 Acute Coronary Syndrome (ACS) Key Players in Central & South America (2019-2020)
12.3 Central & South America Acute Coronary Syndrome (ACS) Market Size by Type (2015-2020)
12.4 Central & South America Acute Coronary Syndrome (ACS) Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Dexa Medica
13.1.1 Dexa Medica Company Details
13.1.2 Dexa Medica Business Overview
13.1.3 Dexa Medica Acute Coronary Syndrome (ACS) Introduction
13.1.4 Dexa Medica Revenue in Acute Coronary Syndrome (ACS) Business (2015-2020))
13.1.5 Dexa Medica Recent Development
13.2 GlaxoSmithKline
13.2.1 GlaxoSmithKline Company Details
13.2.2 GlaxoSmithKline Business Overview
13.2.3 GlaxoSmithKline Acute Coronary Syndrome (ACS) Introduction
13.2.4 GlaxoSmithKline Revenue in Acute Coronary Syndrome (ACS) Business (2015-2020)
13.2.5 GlaxoSmithKline Recent Development
13.3 Novartis
13.3.1 Novartis Company Details
13.3.2 Novartis Business Overview
13.3.3 Novartis Acute Coronary Syndrome (ACS) Introduction
13.3.4 Novartis Revenue in Acute Coronary Syndrome (ACS) Business (2015-2020)
13.3.5 Novartis Recent Development
13.4 Pfizer
13.4.1 Pfizer Company Details
13.4.2 Pfizer Business Overview
13.4.3 Pfizer Acute Coronary Syndrome (ACS) Introduction
13.4.4 Pfizer Revenue in Acute Coronary Syndrome (ACS) Business (2015-2020)
13.4.5 Pfizer Recent Development
13.5 Sanofi
13.5.1 Sanofi Company Details
13.5.2 Sanofi Business Overview
13.5.3 Sanofi Acute Coronary Syndrome (ACS) Introduction
13.5.4 Sanofi Revenue in Acute Coronary Syndrome (ACS) Business (2015-2020)
13.5.5 Sanofi Recent Development
13.6 Serum Institute of India
13.6.1 Serum Institute of India Company Details
13.6.2 Serum Institute of India Business Overview
13.6.3 Serum Institute of India Acute Coronary Syndrome (ACS) Introduction
13.6.4 Serum Institute of India Revenue in Acute Coronary Syndrome (ACS) Business (2015-2020)
13.6.5 Serum Institute of India Recent Development
13.7 Biogen Inc
13.7.1 Biogen Inc Company Details
13.7.2 Biogen Inc Business Overview
13.7.3 Biogen Inc Acute Coronary Syndrome (ACS) Introduction
13.7.4 Biogen Inc Revenue in Acute Coronary Syndrome (ACS) Business (2015-2020)
13.7.5 Biogen Inc Recent Development
13.8 Eli Lilly and Company
13.8.1 Eli Lilly and Company Company Details
13.8.2 Eli Lilly and Company Business Overview
13.8.3 Eli Lilly and Company Acute Coronary Syndrome (ACS) Introduction
13.8.4 Eli Lilly and Company Revenue in Acute Coronary Syndrome (ACS) Business (2015-2020)
13.8.5 Eli Lilly and Company Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Acute Coronary Syndrome (ACS) Key Market Segments
Table 2. Key Players Covered: Ranking by Acute Coronary Syndrome (ACS) Revenue
Table 3. Ranking of Global Top Acute Coronary Syndrome (ACS) Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Acute Coronary Syndrome (ACS) Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Monotherapy
Table 6. Key Players of Combination Therapy
Table 7. Global Acute Coronary Syndrome (ACS) Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Acute Coronary Syndrome (ACS) Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Acute Coronary Syndrome (ACS) Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Acute Coronary Syndrome (ACS) Market Share by Regions (2015-2020)
Table 11. Global Acute Coronary Syndrome (ACS) Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Acute Coronary Syndrome (ACS) Market Share by Regions (2021-2026)
Table 13. Market Top Trends
Table 14. Key Drivers: Impact Analysis
Table 15. Key Challenges
Table 16. Acute Coronary Syndrome (ACS) Market Growth Strategy
Table 17. Main Points Interviewed from Key Acute Coronary Syndrome (ACS) Players
Table 18. Global Acute Coronary Syndrome (ACS) Revenue by Players (2015-2020) (Million US$)
Table 19. Global Acute Coronary Syndrome (ACS) Market Share by Players (2015-2020)
Table 20. Global Top Acute Coronary Syndrome (ACS) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Acute Coronary Syndrome (ACS) as of 2019)
Table 21. Global Acute Coronary Syndrome (ACS) by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Acute Coronary Syndrome (ACS) Product Solution and Service
Table 24. Date of Enter into Acute Coronary Syndrome (ACS) Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Acute Coronary Syndrome (ACS) Market Size by Type (2015-2020) (Million US$)
Table 27. Global Acute Coronary Syndrome (ACS) Market Size Share by Type (2015-2020)
Table 28. Global Acute Coronary Syndrome (ACS) Revenue Market Share by Type (2021-2026)
Table 29. Global Acute Coronary Syndrome (ACS) Market Size Share by Application (2015-2020)
Table 30. Global Acute Coronary Syndrome (ACS) Market Size by Application (2015-2020) (Million US$)
Table 31. Global Acute Coronary Syndrome (ACS) Market Size Share by Application (2021-2026)
Table 32. North America Key Players Acute Coronary Syndrome (ACS) Revenue (2019-2020) (Million US$)
Table 33. North America Key Players Acute Coronary Syndrome (ACS) Market Share (2019-2020)
Table 34. North America Acute Coronary Syndrome (ACS) Market Size by Type (2015-2020) (Million US$)
Table 35. North America Acute Coronary Syndrome (ACS) Market Share by Type (2015-2020)
Table 36. North America Acute Coronary Syndrome (ACS) Market Size by Application (2015-2020) (Million US$)
Table 37. North America Acute Coronary Syndrome (ACS) Market Share by Application (2015-2020)
Table 38. Europe Key Players Acute Coronary Syndrome (ACS) Revenue (2019-2020) (Million US$)
Table 39. Europe Key Players Acute Coronary Syndrome (ACS) Market Share (2019-2020)
Table 40. Europe Acute Coronary Syndrome (ACS) Market Size by Type (2015-2020) (Million US$)
Table 41. Europe Acute Coronary Syndrome (ACS) Market Share by Type (2015-2020)
Table 42. Europe Acute Coronary Syndrome (ACS) Market Size by Application (2015-2020) (Million US$)
Table 43. Europe Acute Coronary Syndrome (ACS) Market Share by Application (2015-2020)
Table 44. China Key Players Acute Coronary Syndrome (ACS) Revenue (2019-2020) (Million US$)
Table 45. China Key Players Acute Coronary Syndrome (ACS) Market Share (2019-2020)
Table 46. China Acute Coronary Syndrome (ACS) Market Size by Type (2015-2020) (Million US$)
Table 47. China Acute Coronary Syndrome (ACS) Market Share by Type (2015-2020)
Table 48. China Acute Coronary Syndrome (ACS) Market Size by Application (2015-2020) (Million US$)
Table 49. China Acute Coronary Syndrome (ACS) Market Share by Application (2015-2020)
Table 50. Japan Key Players Acute Coronary Syndrome (ACS) Revenue (2019-2020) (Million US$)
Table 51. Japan Key Players Acute Coronary Syndrome (ACS) Market Share (2019-2020)
Table 52. Japan Acute Coronary Syndrome (ACS) Market Size by Type (2015-2020) (Million US$)
Table 53. Japan Acute Coronary Syndrome (ACS) Market Share by Type (2015-2020)
Table 54. Japan Acute Coronary Syndrome (ACS) Market Size by Application (2015-2020) (Million US$)
Table 55. Japan Acute Coronary Syndrome (ACS) Market Share by Application (2015-2020)
Table 56. Southeast Asia Key Players Acute Coronary Syndrome (ACS) Revenue (2019-2020) (Million US$)
Table 57. Southeast Asia Key Players Acute Coronary Syndrome (ACS) Market Share (2019-2020)
Table 58. Southeast Asia Acute Coronary Syndrome (ACS) Market Size by Type (2015-2020) (Million US$)
Table 59. Southeast Asia Acute Coronary Syndrome (ACS) Market Share by Type (2015-2020)
Table 60. Southeast Asia Acute Coronary Syndrome (ACS) Market Size by Application (2015-2020) (Million US$)
Table 61. Southeast Asia Acute Coronary Syndrome (ACS) Market Share by Application (2015-2020)
Table 62. India Key Players Acute Coronary Syndrome (ACS) Revenue (2019-2020) (Million US$)
Table 63. India Key Players Acute Coronary Syndrome (ACS) Market Share (2019-2020)
Table 64. India Acute Coronary Syndrome (ACS) Market Size by Type (2015-2020) (Million US$)
Table 65. India Acute Coronary Syndrome (ACS) Market Share by Type (2015-2020)
Table 66. India Acute Coronary Syndrome (ACS) Market Size by Application (2015-2020) (Million US$)
Table 67. India Acute Coronary Syndrome (ACS) Market Share by Application (2015-2020)
Table 68. Central & South America Key Players Acute Coronary Syndrome (ACS) Revenue (2019-2020) (Million US$)
Table 69. Central & South America Key Players Acute Coronary Syndrome (ACS) Market Share (2019-2020)
Table 70. Central & South America Acute Coronary Syndrome (ACS) Market Size by Type (2015-2020) (Million US$)
Table 71. Central & South America Acute Coronary Syndrome (ACS) Market Share by Type (2015-2020)
Table 72. Central & South America Acute Coronary Syndrome (ACS) Market Size by Application (2015-2020) (Million US$)
Table 73. Central & South America Acute Coronary Syndrome (ACS) Market Share by Application (2015-2020)
Table 74. Dexa Medica Company Details
Table 75. Dexa Medica Business Overview
Table 76. Dexa Medica Product
Table 77. Dexa Medica Revenue in Acute Coronary Syndrome (ACS) Business (2015-2020) (Million US$)
Table 78. Dexa Medica Recent Development
Table 79. GlaxoSmithKline Company Details
Table 80. GlaxoSmithKline Business Overview
Table 81. GlaxoSmithKline Product
Table 82. GlaxoSmithKline Revenue in Acute Coronary Syndrome (ACS) Business (2015-2020) (Million US$)
Table 83. GlaxoSmithKline Recent Development
Table 84. Novartis Company Details
Table 85. Novartis Business Overview
Table 86. Novartis Product
Table 87. Novartis Revenue in Acute Coronary Syndrome (ACS) Business (2015-2020) (Million US$)
Table 88. Novartis Recent Development
Table 89. Pfizer Company Details
Table 90. Pfizer Business Overview
Table 91. Pfizer Product
Table 92. Pfizer Revenue in Acute Coronary Syndrome (ACS) Business (2015-2020) (Million US$)
Table 93. Pfizer Recent Development
Table 94. Sanofi Company Details
Table 95. Sanofi Business Overview
Table 96. Sanofi Product
Table 97. Sanofi Revenue in Acute Coronary Syndrome (ACS) Business (2015-2020) (Million US$)
Table 98. Sanofi Recent Development
Table 99. Serum Institute of India Company Details
Table 100. Serum Institute of India Business Overview
Table 101. Serum Institute of India Product
Table 102. Serum Institute of India Revenue in Acute Coronary Syndrome (ACS) Business (2015-2020) (Million US$)
Table 103. Serum Institute of India Recent Development
Table 104. Biogen Inc Company Details
Table 105. Biogen Inc Business Overview
Table 106. Biogen Inc Product
Table 107. Biogen Inc Revenue in Acute Coronary Syndrome (ACS) Business (2015-2020) (Million US$)
Table 108. Biogen Inc Recent Development
Table 109. Eli Lilly and Company Business Overview
Table 110. Eli Lilly and Company Product
Table 111. Eli Lilly and Company Company Details
Table 112. Eli Lilly and Company Revenue in Acute Coronary Syndrome (ACS) Business (2015-2020) (Million US$)
Table 113. Eli Lilly and Company Recent Development
Table 114. Research Programs/Design for This Report
Table 115. Key Data Information from Secondary Sources
Table 116. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Acute Coronary Syndrome (ACS) Market Share by Type: 2020 VS 2026
Figure 2. Monotherapy Features
Figure 3. Combination Therapy Features
Figure 4. Global Acute Coronary Syndrome (ACS) Market Share by Application: 2020 VS 2026
Figure 5. Hospitals Case Studies
Figure 6. Ambulatory Surgical Center Case Studies
Figure 7. Diagnostic Centers Case Studies
Figure 8. Acute Coronary Syndrome (ACS) Report Years Considered
Figure 9. Global Acute Coronary Syndrome (ACS) Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Acute Coronary Syndrome (ACS) Market Share by Regions: 2020 VS 2026
Figure 11. Global Acute Coronary Syndrome (ACS) Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Acute Coronary Syndrome (ACS) Market Share by Players in 2019
Figure 14. Global Top Acute Coronary Syndrome (ACS) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Acute Coronary Syndrome (ACS) as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Acute Coronary Syndrome (ACS) Revenue in 2019
Figure 16. North America Acute Coronary Syndrome (ACS) Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Acute Coronary Syndrome (ACS) Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Acute Coronary Syndrome (ACS) Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Acute Coronary Syndrome (ACS) Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Acute Coronary Syndrome (ACS) Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Acute Coronary Syndrome (ACS) Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Acute Coronary Syndrome (ACS) Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Bottom-up and Top-down Approaches for This Report
Figure 24. Data Triangulation
Figure 25. Key Executives Interviewed
急性冠症候群治療薬の世界市場（～2026年） ACS or Acute coronary syndrome refers to the set of conditions which occurs on account of decreasing flow of blood in coronary arteries owing to which the heart muscle is not able to function. There are various symptoms associated with this condition. The most commonly occurring symptom includes che…- 救急治療センターの世界市場（～2026年） Urgent care center is a type of walk-in clinic that offers ambulatory care in a dedicated medical facility outside of a conventional emergency room (ER). They are mainly used for treating illnesses or injuries that need immediate care, but do not warrant a visit to the ER. They are affordable, quick…
- 冠動脈画像の世界市場（～2026年） Coronary Artery disease (CAD) is a cardiovascular disorder which is caused by reduced flow or absent of blood flow in arteries that enclose and supply the heart which is commonly known as Ischemia. Usually in a coronary artery, due to deposition of fat, cholesterol, and calcium forms a thick layer i…
- 冠動脈バイパス移植片の世界市場（～2026年） Market Analysis and Insights: Global Coronary Artery Bypass Grafts Market The global Coronary Artery Bypass Grafts market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Coronary Artery Bypass Grafts Scope and Market Size Cor…
- 急性虚血性脳卒中治療薬の世界市場（～2026年） AIS is a chronic condition characterized by the sudden loss of blood supply to a part of the brain, thus causing subsequent loss of neurological function. AIS is caused by thrombotic or embolic obstruction of the cerebral artery and is more common than hemorrhagic stroke. The global AIS therapeutics…